OBJECTIVES: The purpose of this study was to examine the clinical effectiveness of aldosterone antagonists in older patients with heart failure and preserved ejection fraction (HF-PEF). BACKGROUND: Aldosterone antagonists improve outcomes in HF and reduced EF. However, their role in HF-PEF remains unclear. METHODS: Of the 10,570 hospitalized older (65 years of age) HF-PEF (EF 40%) patients in the Medicare-linked OPTIMIZE-HF(Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) trial, 8,013 patients had no prior aldosterone antagonist use and no current contraindications; 492 (6% of these 8,013) patients received new prescriptions for aldosterone antagonists. We assembled a matched cohort of 487 pairs of patients receiving and not receiving aldosterone antagonists, who had a similar propensity to receive these drugs and were balanced on 116 baseline characteristics. RESULTS: Patients had a mean age of 80 years old, a mean EF of 54%, 59% were women, and 8% were African American. During 2.4 year of mean follow-up (through December 2008), the primary composite endpoint of all-cause mortality or HF hospitalization occurred in 392 (81%) and 393 (81%) patients receiving and not receiving aldosterone antagonists, respectively (hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.84 to 1.11; p = 0.628). Aldosterone antagonists had no association with all-cause mortality (HR: 1.03; 95% CI: 0.89 to 1.20; p = 0.693) or HF hospitalization (HR: 0.88; 95% CI: 0.73 to 1.07; p = 0.188). Among 8013 prematched patients, multivariable-adjusted HR for the primary composite endpoint associated with aldosterone antagonist use was 0.93 (95% CI: 0.83 to 1.03; p = 0.144). CONCLUSIONS: In older HF-PEF patients, aldosterone antagonists had no association with clinical outcomes. Findings from the ongoing randomized controlled TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial will provide further insights into their effect in HF-PEF.
OBJECTIVES: The purpose of this study was to examine the clinical effectiveness of aldosterone antagonists in older patients with heart failure and preserved ejection fraction (HF-PEF). BACKGROUND:Aldosterone antagonists improve outcomes in HF and reduced EF. However, their role in HF-PEF remains unclear. METHODS: Of the 10,570 hospitalized older (65 years of age) HF-PEF (EF 40%) patients in the Medicare-linked OPTIMIZE-HF(Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) trial, 8,013 patients had no prior aldosterone antagonist use and no current contraindications; 492 (6% of these 8,013) patients received new prescriptions for aldosterone antagonists. We assembled a matched cohort of 487 pairs of patients receiving and not receiving aldosterone antagonists, who had a similar propensity to receive these drugs and were balanced on 116 baseline characteristics. RESULTS:Patients had a mean age of 80 years old, a mean EF of 54%, 59% were women, and 8% were African American. During 2.4 year of mean follow-up (through December 2008), the primary composite endpoint of all-cause mortality or HF hospitalization occurred in 392 (81%) and 393 (81%) patients receiving and not receiving aldosterone antagonists, respectively (hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.84 to 1.11; p = 0.628). Aldosterone antagonists had no association with all-cause mortality (HR: 1.03; 95% CI: 0.89 to 1.20; p = 0.693) or HF hospitalization (HR: 0.88; 95% CI: 0.73 to 1.07; p = 0.188). Among 8013 prematched patients, multivariable-adjusted HR for the primary composite endpoint associated with aldosterone antagonist use was 0.93 (95% CI: 0.83 to 1.03; p = 0.144). CONCLUSIONS: In older HF-PEF patients, aldosterone antagonists had no association with clinical outcomes. Findings from the ongoing randomized controlled TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial will provide further insights into their effect in HF-PEF.
Authors: Dalane W Kitzman; William C Little; Peter H Brubaker; Roger T Anderson; W Gregory Hundley; Christian T Marburger; Bridget Brosnihan; Timothy M Morgan; Kathryn P Stewart Journal: JAMA Date: 2002-11-06 Impact factor: 56.272
Authors: Brita Roy; Ravi V Desai; Marjan Mujib; Andrew E Epstein; Yan Zhang; Jason Guichard; Linda G Jones; Margaret A Feller; Mustafa I Ahmed; Inmaculada B Aban; Thomas E Love; Raynald Levesque; Michel White; Wilbert S Aronow; Gregg C Fonarow; Ali Ahmed Journal: Am J Cardiol Date: 2011-11-24 Impact factor: 2.778
Authors: Yan Zhang; Meredith L Kilgore; Tarun Arora; Marjan Mujib; O James Ekundayo; Inmaculada B Aban; Margaret A Feller; Ravi V Desai; Thomas E Love; Richard M Allman; Gregg C Fonarow; Ali Ahmed Journal: Int J Cardiol Date: 2011-11-25 Impact factor: 4.164
Authors: Margaret A Feller; Marjan Mujib; Yan Zhang; O James Ekundayo; Inmaculada B Aban; Gregg C Fonarow; Richard M Allman; Ali Ahmed Journal: Int J Cardiol Date: 2011-05-31 Impact factor: 4.164
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2003-08 Impact factor: 4.749
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Kanan Patel; Gregg C Fonarow; Momanna Ahmed; Charity Morgan; Meredith Kilgore; Thomas E Love; Prakash Deedwania; Wilbert S Aronow; Stefan D Anker; Ali Ahmed Journal: Circ Heart Fail Date: 2014-10-08 Impact factor: 8.790
Authors: Hossam A Shaltout; Joel Eggebeen; Anthony P Marsh; Peter H Brubaker; Paul J Laurienti; Jonathan H Burdette; Swati Basu; Ashley Morgan; Patricia C Dos Santos; James L Norris; Timothy M Morgan; Gary D Miller; W Jack Rejeski; Amret T Hawfield; Debra I Diz; J Thomas Becton; Daniel B Kim-Shapiro; Dalane W Kitzman Journal: Nitric Oxide Date: 2017-05-23 Impact factor: 4.427
Authors: Essraa Bayoumi; Phillip H Lam; Daniel J Dooley; Steven Singh; Charles Faselis; Charity J Morgan; Samir Patel; Helen M Sheriff; Selma F Mohammed; Carlos E Palant; Bertram Pitt; Gregg C Fonarow; Ali Ahmed Journal: Am J Med Date: 2018-09-19 Impact factor: 4.965
Authors: Kanan Patel; Gregg C Fonarow; O James Ekundayo; Inmaculada B Aban; Meredith L Kilgore; Thomas E Love; Dalane W Kitzman; Mihai Gheorghiade; Richard M Allman; Ali Ahmed Journal: Int J Cardiol Date: 2014-03-11 Impact factor: 4.164